Table 1. Baseline characteristics of participants with early and late syphilis in both groups.
|
Characteristics |
HIV-positive, n (%) |
HIV-negative, n (%) |
||||
|
Early Syphilis |
Late Syphilis |
Total |
Early Syphilis |
Late Syphilis |
Total |
|
|
Gender Male Female Age (Year) Mean ± SD Median (range) Marital Status Married Not married Sexually orientation Heterosexual MSM Bisexual Comorbidities* Gonorrhoeae Condyloma accuminata Vulvovaginal candidiasis Bacterial vaginosis Nonspecific genital infection Lung tuberculosis Papil edema Uveitis Toxoplasma cerebri Pregnancy History of syphilis Yes No History of therapy Benzathine penicillin injection Doxycycline Erythromycin No documented therapy Current therapy Benzathine penicillin 2.4 million IU single dose IM Benzathine penicillin 2.4 million IU 3 times doses IM Doxycycline 2x100mg PO Erythromycin 4x500mg PO Benzathine penicillin injection + doxycycline Benzathine penicillin injection + erythromycin Response to the therapy Serological cure Constant VDRL titer A less 4-fold drop of VDRL Initial 4-fold drop with subsequent 4-fold increase of VDRL Fourfold increase with < 4-fold drop of VDRL Fourfold increase of VDRL without drops CD4+ value Mean ± SD Median (range) ≥500 200-<500 <200 No data Viral load Minimum Maximum 0-499 500-4999 5000-49999 50000-499999 ≥500000 No data |
22 (78.6) 0 (0)
31 ± 9.3 28 (21-57)
3 (10.7) 19 (67.9)
3 (10.7) 16 (57.1) 3 (10.7)
1 (3.6) 3 (10.7) 0 (0) 0 (0) 0 (0) 2 (7.1) 1 (3.6) 1 (3.6) 2 (7.1) 0 (0)
1 (3.6) 21 (75.0)
0 (0) 2 (7.2) 0 (0) 20 (71.4) 14 (50.0) 5 (17.9) 2 (7.1) 0 (0) 1 (3.6) 0 (0)
10 (35.7) 1 (3.6) 8 (28.6) 2 (7.1)
1 (3.6)
0 (0) 251.5 ± 142.9 214.5 (50-538) 1 (3.6) 9 (32.1) 6 (21.4) 6 (21.4)
80 270,762 2 (7.1) 2 (7.1) 0 (0) 1 (3.6) 0 (0) 12 (42.9) |
6 (21.4) 0 (0)
28.2 ± 4.7 28.5 (22-34)
0 (0) 6 (21.4)
2 (7.1) 4 (14.3) 0 (0)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.6) 0 (0)
1 (3.6) 5 (17.9)
1 (3.6) 0 (0) 0 (0) 5 (17.8) 0 (0) 6 (21.4) 0 (0) 0 (0) 0 (0) 0 (0)
2 (7.1) 0 (0) 1 (3.6) 1 (3.6)
0 (0)
2 (7.1) 320 ± 138.1 333 (119-505) 1 (3.6) 3 (10.8) 1 (3.6) 1 (3.6)
<40 88,099 1 (3.6) 0 (0) 1 (3.6) 1 (3.6) 0 (0) 8 (28.6) |
28 (100) 0 (0)
30.3 ± 8.52 28 (21-57)
3 (10.7) 25 (89.3)
5 (17.9) 20 (71.4) 3 10.7)
1 (3.6) 3 (10.7) 0 (0) 0 (0) 0 (0) 2 (7.1) 1 (3.6) 1 (3.6) 3 (10.7) 0 (0)
2 (7.2) 26 (92.9)
1 (3.6) 2 (7.2) 0 (0) 25 (89.2) 14 (50.0) 11 (39.3) 2 (7.1) 0 (0) 1 (3.6) 0 (0)
12 (42.8) 1 (3.6) 9 (32.1) 3 (10.7)
1 (3.6)
2 (7.1) 267.8 ± 141.5 294 (50-538) 2 (7.1) 12 (42.9) 7 (25) 7 (25)
<40 270,762 3 (10.7) 2 (7.1) 1 (3.6) 2 (7.1) 0 (0) 20 (71.5) |
11 (37.9) 2 (6.9)
32.1 ± 9.8 31 (19-57)
6 (20.7) 7 (24.1)
7 (24.15) 5 (17.2) 1 (3.45)
1 (3.45) 0 (0) 1 (3.45) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (6.9)
2 (6.9) 11 (37.9)
1 (3.4) 1 (3.4) 1 (3.4) 10 (34.6) 6 (20.7) 3 (10.3) 3 (10.3) 1 (3.5) 0 (0) 0 (0)
5 (17.2) 1 (3.5) 6 (20.7) 0 (0)
1 (3.5)
0 (0) |
9 (31.1) 7 (24.1)
33.4 ± 11.3 30 (19-66)
12 (41.4) 4 (13.8)
12 (41.35) 3 (10.4) 1 (3.45)
1 (3.45) 1 (3.45) 0 (0) 1 (3.45) 1 (3.45) 0 (0) 0 (0) 0 (0) 0 (0) 2 (6.9)
2 (6.9) 14 (48.3)
2 (6.9) 1 (3.4) 0 (0) 13 (44.9) 0 (0) 14 (48.3) 0 (0) 0 (0) 2 (6.9) 0 (0)
7 (24.1) 3 (10.3) 6 (20.7) 0 (0)
0 (0)
0 (0) |
20 (68) 9 (31)
32.9 ± 10.52 31 (19-66)
18 (62.1) 11 (37.9)
19 (65.5) 8 (27.6) 2 (6.9)
2 (6.9) 1 (3.45) 1 (3.45) 1 (3.45) 1 (3.45) 0 (0) 0 (0) 0 (0) 0 (0) 5 (17.2)
4 (13.8) 25 86.2)
3 (10.3) 2 (6.8) 1 (3.4) 23 (79.5) 6 (20.7) 17 (58.6) 3 (10.3) 1 (3.5) 2 (6.9) 0 (0)
12 (41.3) 4 (13.8) 12 (41.4) 0 (0)
1 (3.5)
0 (0)
|
|
Total |
22 (78.6) |
6 (21.4) |
28 (100) |
13 (44.8) |
16 (55.2) |
29 (100) |
*One patient can have ≥1 comorbidity(ies)